We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development
News

Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development

Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development
News

Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has been awarded a €4.4 M grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). The three-year project entitled "Kinases in Inflammation" aims to accelerate Galapagos' rheumatoid arthritis (RA) programs through clinical Proof of Concept in man.

This project builds on the progress of Galapagos' July 2006 IWT funded project, where new biological models were developed to evaluate the effectiveness of small molecules to treat RA.

The new project will apply these biological models to select compounds for clinical studies. The project also aims to develop and validate biomarkers to monitor disease progression and therapeutic response, which will be applied in the early phases of clinical development.

The grant, which will be distributed over a three-year period, will offset preclinical and phase I/phase IIa clinical costs for Galapagos' RA programs. As part of the project, Galapagos will collaborate with the University of Leuven.

"This grant allows us to accelerate our molecules through preclinical and into phase I and phase IIa development, bringing Galapagos a step closer to delivering novel and effective RA drugs to the patient," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

Advertisement